Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.
Understanding key intervention points in developing immune responses may allow the rational inclusion of biological adjuvants into vaccines that could potentiate the immune response both quantitatively and qualitatively and enhance effective memory responses. Cytokine and chemokine combinations can potentially help target antigen to the appropriate antigen presenting cell and initiate maturation of these presenting cells, attract cells expressing different chemokine receptors, steer cellular immune responses toward Th1 and CD8 CTL, and enhance systemic and mucosal IgG and secretory IgA antibodies and determine their isotype balance. Animal protection studies suggest that synergistic combinations of cytokines and immunomodulating molecules may be required to protect from a viral challenge. For example, GM-CSF has been shown to be synergistic with IL-12 or CD40 ligand for induction of CTL and for antiviral protection, and the triple combination of GM-CSF, IL-12, and TNF alpha appears to induce the most effective protection in some mouse models. Chemokine-antigen fusions have also been shown to enhance immunogenicity of the antigen. Combinations of costimulatory molecules have been found to be synergistic when incorporated in a vaccine. Combined use of newer more potent vaccine constructs, containing codon optimized epitopes, relevant CpG motifs, cytokines, costimulatory molecules and chemokines, used in heterologous prime-boost strategies with viral vector vaccines or recombinant proteins, might afford the most potent vaccine approaches yet developed. In this review we will discuss the application and delivery of cytokines, costimulatory molecules, and chemokines toward improving current vaccine strategies.
Ahlers
Jeffrey D
JD
Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA. jahlers@niaid.nih.gov
Belyakov
Igor M
IM
Berzofsky
Jay A
JA
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000818:Animals; D018925:Chemokines / Q000276:immunology* / Q000378:metabolism; D018899:CpG Islands; D016207:Cytokines / Q000276:immunology* / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D018925:Chemokines; D016207:Cytokines